{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-054587","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.762293+00:00","generated_at":"2026-05-20T04:04:41.423263+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GlycoMimetics supplements merger disclosures; clarifies Crescent selection, $125M PIPE","bullets":["GlycoMimetics chose Crescent over Party A (Chinese parent) due to regulatory clearance timing risks.","Transaction terms: $8M enterprise value for GLYC, $50M for Crescent, $125M concurrent PIPE.","No GlycoMimetics executives will be retained or receive equity post-closing; no financial projections made.","Term Sheet Committee formed with Mr. Junius and Mr. Pearson; dissolved after Merger Agreement execution.","Supplemental tables update precedent IPOs, public companies, M&A, and reverse merger comparisons."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-054587","json":"https://secwatch.observer/filing/0001104659-25-054587.json","markdown":"https://secwatch.observer/filing/0001104659-25-054587.md","text":"https://secwatch.observer/filing/0001104659-25-054587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925054587/0001104659-25-054587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925054587/tm2516580d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T04:04:41.423263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}